Recall Register

Drug recall: Norpace CR (disopyramide phosphate) extended-release capsules USP,150 mg, packaged in a) 100-count bottles (NDC…

Class III FDA enforcement event 72716. Recall start date: . Status in the FDA record: Terminated. Termination date: .

Reason for recall, in the words of FDA

Failed Dissolution Specification

Class III, in the words of FDA

a situation in which use of or exposure to a violative product is not likely to cause adverse health consequences

Pfizer Inc. started this drug recall on 2 Dec 2015. The firm address in the FDA record is in New York, NY. FDA put the recall in Class III. FDA event 72716 has 1 product record. The first FDA enforcement report date is 16 Dec 2015. The record gives the status Terminated, with the termination date 26 Jul 2017.

It is important to note that most of the time recall classifications are determined after the recalling firm provides all of the information needed to determine the risk posed to public health. The classification and posting in the FDA Enforcement Report should not be seen as an expansion or change to a firm’s voluntary public warning.

FDA publishes these words. Source: FDA, Enforcement Reports, Important Note, read on . openFDA export of .

Distribution

In the words of FDA.

Nationwide

Recalling firm

Pfizer Inc., New York, NY.

Recalling firm: The firm that the FDA record names for a recall.

FDA records how the recall started: Voluntary: Firm initiated.

Products

1 product record in the event.

FDA event 72716: product records
Recall numberProductQuantityClassStatusReport date
D-0520-2016Norpace CR (disopyramide phosphate) extended-release capsules USP,150 mg, packaged in a) 100-count bottles (NDC 0025-2742-31), and b) 500-count bottles (NDC 0025-2742-51), Rx only, Distributed by G.D. Searle LLC, Division of Pfizer Inc, NY, NY 10017.a) 4005 bottles, b) 104 bottlesClass IIITerminated16 Dec 2015

openFDA, about the status: FDA does not update the status of a recall after the recall has been classified according to its level of hazard. As such, the status of a recall (open, completed, or terminated) will remain unchanged after published in the Enforcement Reports. Source: openFDA, Drug Recall Enforcement Reports, Disclaimer.

Enforcement report: The FDA publication that lists recalls. It has one record for each product of a recall.

Enforcement event: All the product records that have one FDA event number. This site shows one event on one page.

Class III: The lowest of the three FDA recall classes.

The event in context

Drug events that started in 2015
292
Share of these events in Class III
31%
Product records in this event
1Median of the firm: 1
Events of the firm on the register
72

Other events of the firm

Other FDA enforcement events of Pfizer Inc.
InitiatedProduct (first record)TypeClassRecords
4 Aug 2025Vial Label: Epinephrine Injection, USP, 1mg/10mL (0.1 mg/mL), Rx only, Distributed by Hospira, Inc., Lake Forest, IL 600DrugClass II2
10 Jul 2025Bicillin L-A (penicllin G benzathine injectable suspension), 1,200,000 units per 2 mL, 2 mL-vial, Rx Only, Distributed bDrugClass II2
28 May 2025DOBUTamine Injection, USP, 250 mg/20 mL (12.5 mg/mL), 20 mL per Single-dose Vial, carton of 10 Fliptop Vials, Rx only, FDrugClass II1
20 May 2024Buprenorphine Hydrochloride Injection, 0.3 mg base/mL, 1 mL Single-dose Carpuject, Sterile Cartridge Unit with Luer LockDrugClass II2
21 Dec 20234.2% Sodium Bicarbonate Injection, USP 5 mEq/10 mL (0.5 mEq/mL), Glass ABBOJECT Unit of Use Syringe, For Intravenous UseDrugClass I3
2 Oct 20234.2% Sodium Bicarbonate Injection, USP 5 mEq/10 mL (0.5mEq/mL), Glass ABBOJECT Unit of Use Syringe, packaged as 1 vial aDrugClass I3
8 Mar 2023MEKTOVI (binimetinib) tablets, 15 mg, 180-count bottle, Rx only, Distributed by: Array BioPharma Inc., a wholly owned suDrugClass III1
29 Dec 2022Heparin Sodium 2,000, USP Units, per 1,000 mL (2 USP Units/mL) in 0.9% Sodium Chloride Injection, 1,000 mL bags, a) CaseDrugClass II1
22 Dec 2022Vancomycin Hydrochloride for Injection, USP, 1.5 g/vial, Sterile powder, Single-dose Fliptop Vial, 10 vials per carton, DrugClass I1
27 Sep 2022Aminophylline Injection, USP 250 mg/10 mL (25 mg/mL) 25x10 mL Single-dose vial, Rx only, Distributed by Hospira, Inc. LaDrugClass II1

Pfizer Inc.: all 72 events

Official channels

Cite this page

Recall Register. FDA enforcement event 72716. https://recallregister.com/fda/iii/72716/. Source: openFDA enforcement reports. Data through .

Sources

Source
openFDA drug enforcement reports
Licence
CC0 1.0
Export date
28 Sep 2026
Newest FDA report date on the register
23 Sep 2026

FDA has one record for each product. This site puts the records with the same event number on one page. The class of the event is the highest class of its records. How the register is made. Report an error.

Questions

Where was the product distributed?
The FDA record gives this distribution: Nationwide
What quantity of product is in FDA event 72716?
The FDA record gives this quantity: a) 4005 bottles, b) 104 bottles
How did the recall start?
The FDA record says: Voluntary: Firm initiated
How many drug recalls of 2015 have the same class?
31% of the 292 drug events that started in 2015 are in Class III.